{
    "id": 26996,
    "fullName": "TGFBR2 L452M",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TGFBR2 L452M lies within the protein kinase domain of the Tgfbr2 protein (UniProt.org). L452M confers a loss of function to the Tgfbr2 protein as indicated by failure to induce mesoderm formation in response to Tgf-beta1 in Xenopus embryos (PMID: 11212236).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9922,
                    "pubMedId": 11212236,
                    "title": "Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11212236"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7048,
        "geneSymbol": "TGFBR2",
        "terms": [
            "TGFBR2",
            "AAT3",
            "FAA3",
            "LDS1B",
            "LDS2",
            "LDS2B",
            "MFS2",
            "RIIC",
            "TAAD2",
            "TBR-ii",
            "TBRII",
            "TGFbeta-RII",
            "TGFR-2"
        ]
    },
    "variant": "L452M",
    "createDate": "09/15/2017",
    "updateDate": "09/15/2017",
    "referenceTranscriptCoordinates": {
        "id": 130887,
        "transcript": "NM_003242",
        "gDna": "chr3:g.30674204C>A",
        "cDna": "c.1354C>A",
        "protein": "p.L452M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11938,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the TGFBR2 L452M variant was identified in tumor samples of Nolvadex (tamoxifen)-resistant breast cancer patients, which may mediate Nolvadex (tamoxifen)-resistance through inhibition of Tgf-beta1 signaling (PMID: 11212236).",
            "molecularProfile": {
                "id": 28363,
                "profileName": "TGFBR2 L452M"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9922,
                    "pubMedId": 11212236,
                    "title": "Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11212236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28363,
            "profileName": "TGFBR2 L452M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 130887,
            "transcript": "NM_003242",
            "gDna": "chr3:g.30674204C>A",
            "cDna": "c.1354C>A",
            "protein": "p.L452M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}